KRAS mutations, although found in a lower percentage (11.5%) of bladder cancers, are assuming a relevant position since the detection of KRAS mutations in conjunction with the previous alterations could improve the sensitivity of a biomarker panel (Alexander et al., 2012). This evidence concerns the gene KRAS and urinary bladder carcinoma.